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The aim of this study was to estimate a 48 hour prediction of moderate to severe respiratory
failure, requiring mechanical ventilation, in hospitalized patients with COVID-19 pneumonia.
Methods
This was an observational prospective study that comprised consecutive patients with
COVID-19 pneumonia admitted to hospital from 21 February to 6 April 2020. The patients’
medical history, demographic, epidemiologic and clinical data were collected in an electronic
patient chart. The dataset was used to train predictive models using an established machine
learning framework leveraging a hybrid approach where clinical expertise is applied along-
side a data-driven analysis. The study outcome was the onset of moderate to severe respi-
ratory failure defined as PaO2/FiO2 ratio <150 mmHg in at least one of two consecutive
arterial blood gas analyses in the following 48 hours. Shapley Additive exPlanations values
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were used to quantify the positive or negative impact of each variable included in each
model on the predicted outcome.
Results
A total of 198 patients contributed to generate 1068 usable observations which allowed to
build 3 predictive models based respectively on 31-variables signs and symptoms, 39-vari-
ables laboratory biomarkers and 91-variables as a composition of the two. A fourth “boosted
mixed model” included 20 variables was selected from the model 3, achieved the best pre-
dictive performance (AUC = 0.84) without worsening the FN rate. Its clinical performance
was applied in a narrative case report as an example.
Conclusion
This study developed a machine model with 84% prediction accuracy, which is able to assist
clinicians in decision making process and contribute to develop new analytics to improve
care at high technology readiness levels.
Background
COVID-19 pandemic found all health care system inadequately prepared and urges the need
for new tools to face this unprecedented public health and clinical emergency. The clinical
complexity of COVID-19 ranges from asymptomatic cases to severe pneumonia [1–3] whose
progression to respiratory failure is difficult to predict. Pneumonia mostly occurs in the second
or third week of a symptomatic infection and it is characterized by a mortality rate of 3–10%,
which increases risk of multiorgan failure and mechanical ventilation [4]. Patients most com-
monly report the sudden onset of dyspnea during daily activities or rest. Prominent clinical
signs include respiratory rate� 30 breaths per minute, blood oxygen saturation� 93%, partial
pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2)< 300 mmHg.
This is an initial phase of acute respiratory distress syndrome (ARDS) that progressively leads
to moderate to severe respiratory failure [4].
Overall, there is a high degree of uncertainty both in the progression of the patient’s health
status and in the speed at which patients develop respiratory failure requiring mechanical
ventilation.
Machine learning methods such as those employed to create the model have shown poten-
tial to produce predictive models that can be applied to assist and improve clinical decisions
for a broad variety of outcomes [5, 6], and have recently been used in response to the COVID-
19 emergency [7–9].
However, the most comprehensive review to date [9] finds that some risk prediction models
attempt to predict risk of intensive care unit admission, ventilation, intubation, but most of
these studies have shortcomings (high bias, poor reporting) that make them unsuitable for
clinical decision-making. In contrast, the models presented in this work are explainable, mean-
ing that they provide an easily understandable grounding for the choice of predictors and their
relative importance on individual outcomes.
The aim of this study was to have a 48-hour prediction of moderate to severe respiratory
failure, requiring mechanical ventilation, in hospitalized patients with COVID-19 pneumonia.
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Methods
Study design
This observational prospective single center study included consecutive adult patients (�18
years) admitted to Infectious Disease Clinic of the University Hospital of Modena, Italy from
21 February to 6 April 2020 with radiologically findings suggestive for COVID-19 pneumonia
and confirmed by PCR method on nasopharyngeal swab.
All patients received treatment according to the Italian Society of Infectious Diseases’
Guidelines (SIMIT) recommendations [10] including oxygen supply to target SaO2 > 90%;
hydroxychloroquine with or without azithromycin, and low molecular weight heparin. Lopi-
navir/ritonavir or darunavir/cobicistat was also used up to 18 March, when a clinical trial on
the former did not show any benefit of protease inhibitors against the standard of care [11].
The study outcome was the onset of moderate to severe respiratory failure defined as PaO2/
FiO2 ratio < 150 mmHg (� 13.3 kPa) in at least one of two consecutive arterial blood gas anal-
yses in the following 48 hours.
Data source
Hospitalized patients with COVID-19 pneumonia were included if they had at least two arte-
rial blood gas analyses measurements in the following 48 hours.
The patients’ full medical history including chronic comorbidities, demographic and epide-
miological data were obtained at the hospital admission. Clinical data with signs and symp-
toms and complete blood count, coagulation, inflammatory and biochemical markers were
routinely collected in the electronic patient charts.
Given the strict time dependent outcome definition, out of the initial sample of 295 patients
and 2,889 data points available, 198 patients contributed to generate 1068 valuable observa-
tions. In detail, 603 observations contributed to the definition of respiratory failure (PaO2/
FiO2 < 150 mmHg) and 465 did not meet this definition.
In the data collection period, the dataset was growing daily with the average of 84 new rec-
ords per day, with a mean of 10 new data points/patient. Each data point included a complex
record of observations from multiple categories: (1) signs and symptoms, (2) blood biomark-
ers, (3) respiratory assessment with PaO2/FiO2, (4) history of comorbidities (available in a sub-
set of 119 patients). Some variables were collected daily, and others were recorded upon
clinical indications.
All patients provided verbal, not written, informed consent due to isolation precautions.
The study was approved by Regional ethical committee of Emilia Romagna (Area Vasta Nord
protocol 426/2020).
Prediction models / machine learning methods
To be considered viable for clinical use, a predictive model must not only be accurate, it must
also be (1) parsimonious, that is, it must achieve its accuracy using the minimal number of var-
iables; (2) robust to missing data, an important feature in clinical emergency setting where not
all observations are complete at each assessment; (3) transparent, in the sense that the model
reveals the relative importance of each variable for each prediction it makes, which may be dif-
ferent for different patients. This is particularly important in clinical settings as it enables
healthcare professionals to interpret the pathophysiological relationships between variables,
arguably resulting in an increased trust in the model’s predictions.
Finally, the model should (4) minimize the number of false negatives (FN), that is, the risk
of under-estimating the severity of a patient’s condition.
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To address the first requirement, the study produced a suite of four competing candidate
models, based on aggregations of the observations into different datasets. Specifically, Model 1
was based solely on variables for first signs and symptoms; Model 2 on blood biomarkers
excluding PaO2/FiO2, and Model 3 and 4 using both sets of variables, including comorbidities.
This experimental design enables a comparison of the relative predictive performance across
categories of variables. Furthermore, the ranking of the variables by their predictive power
makes it possible to achieve a parsimonious model by eliminating the least relevant variables,
resulting in an effective yet parsimonious model.
To address the second and third requirements, the LightGBM suite of algorithms (Micro-
soft) [12] was used. These algorithms are based on well-known ensembles of Decision Trees,
and are able to produce binary classification models (positive vs negative outcome) which tol-
erate missing data, and which support intelligible explanations on how the model achieves its
predictions.
Meeting the final goal of minimizing FN (4) required that a specialized loss function be
developed specifically for this task. This is a function that the algorithm must minimize in
order to produce optimal predictions, and in this case it includes a tunable parameter to con-
trol the ratio of FP to FN.
For this binary classifier we used the PaO2/FiO2 ratio to derive a binary outcome for the
learning task, where a positive outcome is defined as PaO2/FiO2� 150, and negative PaO2/
FiO2 < 150. These are referred to as the positive and negative classes, respectively.
Following best practices, the dataset was divided into two parts: the training set (75% of the
data—801 samples, of which 452 with PaO2/FiO2 < 150) and a complementary test set (the
remaining 25% - 267 samples, of which 151 with PaO2/FiO2 < 150), which was not used in the
learning phase. This separation was stratified according to the distribution of the outcome, in
order to maintain a constant ratio between positive and negative classes in each of the subsets.
The training set was used as input to the ML algorithm to train the model, while the test set is
used to verify the predictive performance using standard metrics. The test set provided inde-
pendent ground truth where each instance (a patient’s set of observations) was associated with
one of the two possible outcomes. This test set was used to evaluate the predictive performance
of the model, defined in terms of true positives (TP), true negatives (TN), false negatives (FN),
false positives (FP).
Model performance was measured both on the AUROC and the sensitivity. The LightGBM
algorithm not only allowed tuning of their hyper-parameters (these are the parameters that
cannot be learnt by the algorithm and must be set manually) in order to maximize perfor-
mance, but they also allowed more specific optimization targets than simply accuracy. For this
application, clinical priority was followed to maximize the sensitivity, defined as TPTPþFN. Stan-
dard 5- and 10-fold cross validation was used to tune the model hyperparameters to achieve
this goal.
To meet requirement (3) above, the learning framework provides explanations that go
beyond the simple ranking of the variables. Specifically, the framework generates SHapley
Additive exPlanations (SHAP) values quantifying the impact of each variable on the predicted
outcome under different perspectives and both across the entire population and for individual
patients [13].
Results
Out of a total of 295 patients, 198 with COVID-19 pneumonia were included. Clinical and lab-
oratory characteristics are shown in Table 1. The vast majority of patients were males (69.2%)
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with a median age of 65 years. All patients showed relevant respiratory impairment as
expressed by a median PaO2/FiO2: 262 mmHg (IQR: 150.0–316.0).
To recollect, all models are binary (yes/no) classifiers of risk of developing respiratory fail-
ure, measured using a quantitative criterion (PaO2/FiO2 < 150 mmHg) and assessed using
AUC and sensitivity. Also, a specific loss function was developed to privilege models that mini-
mize the number of false negatives (FN).
Table 2 describes the four models that were used to train and test the ML tool with the fol-
lowing features:
Model 1: “signs and symptoms” that included 31 variables
Model 2: “laboratory biomarkers” that included 39 variables.
Model 3: “extended mixed model” that included 91 variables.
Model 4: “boosted mixed model” that includes 20 variables.
The latter was obtained from Model 3, achieving the same performance, and equal number
of FN, with only 20 variables out of 91 of Model 3. To achieve this result, the variables of
Model 3 were ranked according to their mean SHAP values and a backward variable selection
approach was adopted, by which each variable was excluded in turn, starting from the lowest-
ranked variables, and the loss in predictive performance was measured each time. This proce-
dure identified Model 4 as the one that minimized the number of variables (20 out of the
Table 1. Clinical and laboratory characteristics of the study population at the time of hospital admission.
Variable Mean or median or %
Population (%) 198 (100%)
Age, years, median (IRQ) 62.0 (54.0–73.0)
Sex, males (%) 151 (76.26%)
Signs and symptoms
Cough (%) 125 (63.33%)
Temperature, ˚C, median (IRQ) 37.0 (36.25–38.0)
Dyspnea (%) 135 (68.85%)
Diarrhea (%) 34 (17.19%)
Respiratory rate per minute, median (IRQ) 22.0 (18.75–28.0)
Biomarkers
Creatinine, mg/dl, median (IRQ) 0.92 (0.8–1.27)
D-Dimer, ng/ml, median (IRQ) 1120.0 (645.0–1767.5)
Hemoglobin, g/dl, median (IRQ) 13.85 (12.7–14.5)
Platelets, x109 per L, median (IRQ) 181.0 (154.5–258.5)
White Blood Cells, x1012 per L, median (IRQ) 6.92 (4.92–8.47)
PaO2, %, median (IRQ) 65.2 (56.9–76.6)
PaO2/FiO2, mmHg, median (IRQ) 256.0 (149.75–301.5)
Oxygen saturation, %, median (IRQ) 94.0 (91.65–95.75)
Creatinine kinase, U/L, median (IRQ) 107.0 (60.25–261.75)
Lactate dehydrogenase, U/L, median (IRQ) 562.0 (458.0–663.0)
C-reactive protein, mg/dl, median (IRQ) 7.35 (4.22–17.65)
Abbreviations: IQR–interquartile range; FiO2 –fraction of inspired oxygen; PaO2 –partial arterial pressure of
oxygen.
https://doi.org/10.1371/journal.pone.0239172.t001
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original 91) without worsening the FN rate, while achieving the best performance
(AUROC = 0.84). S1 Fig specifies the description of the proportion of available data for each of
the 20 variables.
For each model, Table 2 reports the Area Under the Curve (AUC) for both training and test
sets. We indicate the number of TP, TN, FN, FP. Variables included in each model are listed in
S1 File. Figs 1 and 2 show the top 20 ranking variables used to train Model 4. X axes show the
average impact of model output magnitude, expressed by SHAP values.
Case presentation to support customization of ML into clinical practice
In addition to the theoretical performance, anecdotal validation was also provided in a real-life
case setting. We applied our model to the clinical course of a 55-year-old male who was admit-
ted for high fever and shortness of breath due to COVID-19 pneumonia. Antiviral therapy
with darunavir/cobicistat was started in addition to hydroxychloroquine. He was discharged
the following day, in the absence of respiratory failure as assessed by PaO2/FiO2 = 420 mmHg.
Four days later, he was readmitted to hospital with high fever (39˚C), diarrhea and onset of
mild respiratory failure (PaO2/FiO2 = 230 mmHg). Inflammatory biomarkers were high (CRP
18 mg/dl) with elevated neutrophils. In the following 24 hours, the patient experienced a clini-
cally unpredictable dramatic worsening of his clinical condition due to the onset of severe
respiratory distress despite adequate oxygen supply (PaO2/FiO2 = 88 mmHg, respiratory rate
higher than 35 breaths per minute). He was then transferred to the Intensive Care Unit (ICU)
where non-invasive mechanical ventilation with helmet in pressure support mode was initi-
ated. After 8 days of assisted spontaneous breathing, he was weaned from NIV and discharged
the following day without oxygen supply (Fig 3).
As shown in the case scenario presented above, the model was retrospectively applied in
order to explore the prediction of “respiratory crush” in support of clinical judgment. From
the physician’s point of view, the first discharge was motivated by the stable clinical conditions.
Table 2. Describes the four models that were used to train and test the ML tool.
Table legend AUROC (%)
Actual Good Outcome Actual Good Outcome Training model: %
Actual Good Outcome TN FP Test model: %
Actual Bad Outcome FN TP
Model 1 –Only signs and symptoms, 31 variables Model 1
Actual Good Outcome Actual Good Outcome Training model: 89%
Actual Good Outcome 74—TN 42 FP Test model: 69%
Actual Bad Outcome 56 FN 95 TP
Model 2 –Laboratory biomarkers, 39 variables Model 2
Predicted Good Outcome Predicted Bad Outcome Training model: 97%
Actual Good Outcome 89 27 Test model: 83%
Actual Bad Outcome 39 112
Model 3 –Extended mixed model, 91 variables Model 3
Predicted Good Outcome Predicted Bad Outcome Training model: 99%
Actual Good Outcome 95 21 Test model: 85%
Actual Bad Outcome 40 111
Model 4 –Boosted mixed model, 20 variables Model 4
Predicted Good Outcome Predicted Bad Outcome Training model: 98%
Actual Good Outcome 87 29 Test model: 84%
Actual Bad Outcome 40 111
https://doi.org/10.1371/journal.pone.0239172.t002
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Fig 1. Shows top 20 ranking variables used to train Model 4. X axes show the average impact of model output magnitude, expressed by SHAP values.
https://doi.org/10.1371/journal.pone.0239172.g001
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However, our model showed a 36.6% probability of worsening of the respiratory function in
the following 48 hours, meeting the criteria for mechanical ventilation with pressure support
in the next two days. Moreover, the model was able to predict at the time of the second admis-
sion, the respiratory function decline that our patient actually experienced 24 hours later. The
model at day 14 predicted a 47.4% risk of new worsening, but this should have been integrated
with clinical data suggested by patient’s perception of improvement and rapid increase of
blood gas exchange. A development of our support model at the time into our clinical practice
would have provided support to clinical judgment, suggesting against the first discharge, and
furthermore, recommending continuous monitoring once the patient was readmitted in order
to possibly avoid ICU with urgent treatment.
Discussion
We have created a statistical learning model to assist clinicians in forecasting patients with
COVID-19 who develop respiratory failure requiring mechanical ventilation. The model pro-
vide a reliable 48 hours prediction of moderate to severe respiratory failure, with an accuracy
of 84% that minimizes the FN rate.
Fig 2. The individual SHAP values for the 20 top variables. Values of each variable may have a positive or negative impact depending on their SHAP value, for
instance high values of dyspnea in red contribute strongly to the positive class (negative patient outcome), while low values in blue contribute strongly to the negative
class (positive outcome).
https://doi.org/10.1371/journal.pone.0239172.g002
Fig 3. Implementation of machine learning model in the case of 55-year old patient who was admitted and discharged the following day. On day 4, the patient was
re-admitted with mild respiratory insufficiency that had a 87.7% probability to experience a respiratory crush in the following 48 hours.
https://doi.org/10.1371/journal.pone.0239172.g003
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The level of performance of our model is in line with other ML tools used in different areas
of medicine [14, 15] and it is very useful in COVID-19 clinical context where disease progres-
sion remains unpredictable both in the early virologic and in the late inflammatory phase.
It must be acknowledged that risk probability generated from the algorithm at each time
point is not a measure of overall performance of the model. Clinicians should not interpret the
punctual probability score as a diagnosis but rather to asses the trend measure, integrating the
data in the context of clinical judgment.
We chose to have a short-term outcome to support clinicians at hospital admission and dis-
charge. Given the rapid and dynamic clinical changes affecting COVID-19 patients, this time
frame should be considered crucial for the initiation of therapies aimed at avoiding ICU
admission and mechanical ventilation. In the future we may be able to develop similar models
to also support clinicians to better interpret patient’s clinical improvement after they are dis-
charged from hospital.
The construction of different models followed a clinically oriented variables choice. The
first model based on 31 variables obtained from signs and symptoms returned a suboptimal
prediction accuracy. Adding biomarkers including respiratory variables significantly increased
the forecasting capacity of the model. The best performance was obtained in the boosted
mixed model, which however still requires about 20 variables. From a physician’s perspective,
a cluster of 20 variables may be difficult to manage in routine clinical practice. What our
approach offers in support to the decision-making process is a simple interpretation of the
predictions.
Machine learning approach is at the top of the list of the research priorities proposed by the
Horizon 2020 program (H2020) [16]. This study may contribute to develop new analytics to
improve care at high technology readiness levels.
Moderate to severe respiratory failure was chosen as an outcome being the most relevant
time point in the natural history of severe COVID-19 pneumonia. At a clinical level, it repre-
sents the so-called “respiratory crush” which marks acute lung injury and leads to mechanical
ventilation in ICU. At a public health level, this machine learning model might be helpful in
optimizing scarce resources like ventilators and ICU beds.
A few clinical risk scores have been developed and validated to predict the occurrence of
critical illness in hospitalized patients with COVID-19. These scores used at time of admission
either the neutrophil/lymphocyte ratio or 10 clinical variables including radiological findings
to predict critical illness using a traditional statistical approach to generate a prediction algo-
rithm [17, 18].
In a similar experience from China, ML was used to predict mortality in patients with
COVID-19, using three biomarkers only [7].
Recent data suggests that COVID-19 does not affect only respiratory system, but also other
organs, such as liver, kidneys, gut, heart and central nervous system [19].
Given the multisystemic nature of this disease, limited number of parameters may not be
sufficient to predict worsening in these patients.
Not surprisingly, this hard endpoint can be predicted with a very limited number of bio-
markers, reducing the clinical parameters to be monitored. However, clinical worsening seems
to be more challenging to forecast. An intermediate dynamic event with multiple biomarkers
appears to be more difficult to predict than a final static event, such as mortality, with a small
number of variables.
This science data faced several methodological challenges. Features which fed the model
were chosen based both on the Shapley Values approach and on clinicians’ suggestion, in a
hybrid approach. This allowed to take advantage of both aspects: on one side the clinical
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experience of physicians who selected variables and outcomes using a knowledge-based
approach, and on the other side, the probabilistic nature of a data-driven framework.
Microsoft LightGBM framework was chosen in particular to support missing data deriving
from a clinical setting where it was not practical to collect all observations at each data point.
Clinicians appreciated the “Glass box” opportunity, which showed the top variables, trusting a
model in which pathophysiological interpretation could still be plausible. With regards to the
20 variables selected in the hybrid models, some can be clustered within the hypoxic damage
(dyspnea, HCO3-, pH, reparatory and heart rate) other in relation to inflammation (C-reactive
protein, D-dimer, platelets, red blood cells, lymphocytes), other in relation to organ damage
(lactate dehydrogenase, creatinine-kinase). Medical Decision Support Systems must provide
transparency to explain how the predictive model behaves. In this perspective, an interpreta-
tion approach is necessary, both to have better understanding of the patient’s health status and
to better identify dangerous biases that the model could have learnt.
The approach in our study is substantially different from traditional models based on logis-
tic regression [20]. Risk scores derived from logistic regression mixed effect models are knowl-
edge-driven approaches where a score is assigned by an expert to each of the limited number
of selected variables [21]. In contrast, our predictive model is data driven. It is based on Deci-
sion Trees, in which the relative effect of all available variables is considered with their raw
value instead of an arbitrary summarization.
This approach is particularly appropriate in COVID-19 context as it aligns well with princi-
ples of personalized medicine. It allows to identify what are the most relevant biomarkers for
each individual patient which in a single patient can lead to a favorable or un-favorable pro-
gression, as shown by the Shapley Values application in Fig 3. This confirms the expected rela-
tive importance (ranking) of the variables used as features and the roles of those features in the
model. This is a further proof that the model is robust as it relies on the values of variables
deemed relevant in this context without actually knowing their semantics.
Our study has several limitations. Firstly, it does not take account of radiological findings
on X-rays or CT, as these data were not collected consistently during hospital stay. Neverthe-
less, a recent radiological study demonstrated only a slight increase of prediction of respiratory
failure adding thoracic CT to clinical data [22].
Secondly, we chose as outcome a cut-off of PaO2/FiO2 which represents one of the most
important criteria for invasive mechanical ventilation, but not mechanical ventilation itself.
Also, the model is oblivious to a whole panel of interleukins values, as they were not collected
on daily basis regardless of their potential involvement in the development of severe respira-
tory failure. Lastly, the model will need to evolve with the growth of the dataset, providing a
more accurate cut-off risk value.
In conclusion, this study developed a machine learning algorithm aimed to assist clinicians
in dealing with COVID-19 health emergency. It is proving useful in predicting severe respira-
tory failure requiring mechanical ventilation in the following 48 hours, allowing to anticipate
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